Nuvectis Ebitda vs Cost Of Revenue Analysis

NVCT Stock

USD 4.95 0.15 2.94%

Nuvectis Pharma financial indicator trend analysis is infinitely more than just investigating Nuvectis Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nuvectis Pharma is a good investment. Please check the relationship between Nuvectis Pharma Ebitda and its Cost Of Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvectis Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Nuvectis Stock please use our How to Invest in Nuvectis Pharma guide.

Ebitda vs Cost Of Revenue

Ebitda vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nuvectis Pharma Ebitda account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Nuvectis Pharma's Ebitda and Cost Of Revenue is -0.92. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Nuvectis Pharma, assuming nothing else is changed. The correlation between historical values of Nuvectis Pharma's Ebitda and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Nuvectis Pharma are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Ebitda i.e., Nuvectis Pharma's Ebitda and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.92

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Ebitda

Cost Of Revenue

Cost of Revenue is found on Nuvectis Pharma income statement and represents the costs associated with goods and services Nuvectis Pharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Nuvectis Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nuvectis Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvectis Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Nuvectis Stock please use our How to Invest in Nuvectis Pharma guide.Enterprise Value is likely to gain to about 116.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.6 M in 2024.

	2010	2022	2023	2024 (projected)
Interest Income	4K	149K	475K	498.8K
Net Interest Income	4K	149K	475K	498.8K

Interest Income Net Interest Income

Nuvectis Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Net Debt	Non Currrent Assets Other	Other Assets	Other Stockholder Equity	Deferred Long Term Liab	Retained Earnings Total Equity	Capital Surpluse	Common Stock
Total Assets		0.95	0.96	0.88	0.88	-0.9	0.97	1.0	-0.97	1.0	0.67	-0.01	0.55	0.43	0.88	1.0	0.98	-0.97	-0.56	-0.56	0.97	-0.56	0.69	-0.56	0.66
Other Current Liab	0.95		1.0	0.73	0.77	-0.95	0.99	0.96	-0.94	0.96	0.76	0.21	0.38	0.64	0.73	0.95	0.98	-0.93	-0.62	-0.62	0.97	-0.62	0.78	-0.62	0.74
Total Current Liabilities	0.96	1.0		0.74	0.77	-0.94	1.0	0.96	-0.94	0.96	0.72	0.22	0.44	0.64	0.74	0.96	0.99	-0.94	-0.6	-0.6	0.96	-0.6	0.74	-0.6	0.71
Total Stockholder Equity	0.88	0.73	0.74		0.99	-0.77	0.74	0.88	-0.9	0.88	0.64	-0.45	0.42	0.03	1.0	0.88	0.79	-0.9	-0.64	-0.64	0.86	-0.64	0.63	-0.64	0.67
Net Tangible Assets	0.88	0.77	0.77	0.99		-0.84	0.77	0.88	-0.92	0.88	0.75	-0.41	0.31	0.11	0.99	0.88	0.8	-0.92	-0.73	-0.73	0.9	-0.73	0.73	-0.73	0.77
Retained Earnings	-0.9	-0.95	-0.94	-0.77	-0.84		-0.92	-0.9	0.96	-0.9	-0.88	-0.1	-0.18	-0.61	-0.77	-0.89	-0.91	0.95	0.83	0.83	-0.96	0.83	-0.86	0.83	-0.9
Accounts Payable	0.97	0.99	1.0	0.74	0.77	-0.92		0.97	-0.95	0.97	0.67	0.24	0.5	0.64	0.74	0.97	1.0	-0.94	-0.57	-0.57	0.94	-0.57	0.68	-0.57	0.66
Cash	1.0	0.96	0.96	0.88	0.88	-0.9	0.97		-0.97	1.0	0.68	-0.01	0.54	0.43	0.88	1.0	0.98	-0.97	-0.56	-0.56	0.97	-0.56	0.7	-0.56	0.66
Non Current Assets Total	-0.97	-0.94	-0.94	-0.9	-0.92	0.96	-0.95	-0.97		-0.97	-0.76	0.03	-0.41	-0.46	-0.9	-0.97	-0.95	1.0	0.74	0.74	-0.97	0.74	-0.75	0.74	-0.78
Cash And Short Term Investments	1.0	0.96	0.96	0.88	0.88	-0.9	0.97	1.0	-0.97		0.68	-0.01	0.54	0.43	0.88	1.0	0.98	-0.97	-0.56	-0.56	0.97	-0.56	0.7	-0.56	0.66
Common Stock Shares Outstanding	0.67	0.76	0.72	0.64	0.75	-0.88	0.67	0.68	-0.76	0.68		-0.13	-0.25	0.38	0.64	0.67	0.64	-0.75	-0.87	-0.87	0.83	-0.87	0.99	-0.87	0.98
Non Current Liabilities Total	-0.01	0.21	0.22	-0.45	-0.41	-0.1	0.24	-0.01	0.03	-0.01	-0.13		0.13	0.84	-0.45	-0.01	0.17	0.03	0.12	0.12	-0.04	0.12	-0.12	0.12	-0.13
Other Current Assets	0.55	0.38	0.44	0.42	0.31	-0.18	0.5	0.54	-0.41	0.54	-0.25	0.13		0.13	0.42	0.55	0.56	-0.43	0.23	0.23	0.33	0.23	-0.23	0.23	-0.24
Total Liab	0.43	0.64	0.64	0.03	0.11	-0.61	0.64	0.43	-0.46	0.43	0.38	0.84	0.13		0.03	0.43	0.58	-0.46	-0.4	-0.4	0.44	-0.4	0.37	-0.4	0.41
Net Invested Capital	0.88	0.73	0.74	1.0	0.99	-0.77	0.74	0.88	-0.9	0.88	0.64	-0.45	0.42	0.03		0.88	0.79	-0.9	-0.64	-0.64	0.86	-0.64	0.63	-0.64	0.67
Total Current Assets	1.0	0.95	0.96	0.88	0.88	-0.89	0.97	1.0	-0.97	1.0	0.67	-0.01	0.55	0.43	0.88		0.98	-0.97	-0.56	-0.56	0.97	-0.56	0.69	-0.56	0.66
Net Working Capital	0.98	0.98	0.99	0.79	0.8	-0.91	1.0	0.98	-0.95	0.98	0.64	0.17	0.56	0.58	0.79	0.98		-0.95	-0.55	-0.55	0.95	-0.55	0.65	-0.55	0.63
Net Debt	-0.97	-0.93	-0.94	-0.9	-0.92	0.95	-0.94	-0.97	1.0	-0.97	-0.75	0.03	-0.43	-0.46	-0.9	-0.97	-0.95		0.74	0.74	-0.96	0.74	-0.73	0.74	-0.78
Non Currrent Assets Other	-0.56	-0.62	-0.6	-0.64	-0.73	0.83	-0.57	-0.56	0.74	-0.56	-0.87	0.12	0.23	-0.4	-0.64	-0.56	-0.55	0.74		1.0	-0.69	1.0	-0.8	1.0	-0.95
Other Assets	-0.56	-0.62	-0.6	-0.64	-0.73	0.83	-0.57	-0.56	0.74	-0.56	-0.87	0.12	0.23	-0.4	-0.64	-0.56	-0.55	0.74	1.0		-0.69	1.0	-0.8	1.0	-0.95
Other Stockholder Equity	0.97	0.97	0.96	0.86	0.9	-0.96	0.94	0.97	-0.97	0.97	0.83	-0.04	0.33	0.44	0.86	0.97	0.95	-0.96	-0.69	-0.69		-0.69	0.84	-0.69	0.81
Deferred Long Term Liab	-0.56	-0.62	-0.6	-0.64	-0.73	0.83	-0.57	-0.56	0.74	-0.56	-0.87	0.12	0.23	-0.4	-0.64	-0.56	-0.55	0.74	1.0	1.0	-0.69		-0.8	1.0	-0.95
Retained Earnings Total Equity	0.69	0.78	0.74	0.63	0.73	-0.86	0.68	0.7	-0.75	0.7	0.99	-0.12	-0.23	0.37	0.63	0.69	0.65	-0.73	-0.8	-0.8	0.84	-0.8		-0.8	0.95
Capital Surpluse	-0.56	-0.62	-0.6	-0.64	-0.73	0.83	-0.57	-0.56	0.74	-0.56	-0.87	0.12	0.23	-0.4	-0.64	-0.56	-0.55	0.74	1.0	1.0	-0.69	1.0	-0.8		-0.95
Common Stock	0.66	0.74	0.71	0.67	0.77	-0.9	0.66	0.66	-0.78	0.66	0.98	-0.13	-0.24	0.41	0.67	0.66	0.63	-0.78	-0.95	-0.95	0.81	-0.95	0.95	-0.95

Click cells to compare fundamentals

Nuvectis Pharma Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Nuvectis Stock Analysis

When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nuvectis Ebitda vs Cost Of Revenue Analysis

Ebitda vs Cost Of Revenue

Ebitda vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Ebitda

Cost Of Revenue

Nuvectis Pharma fundamental ratios Correlations

Nuvectis Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Nuvectis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Accounts Payable	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity

Net Debt	- 0.97	Total Current Assets
Net Debt	- 0.97	Cash And Short Term Investments
Other Stockholder Equity	- 0.97	Non Current Assets Total
Total Current Assets	- 0.97	Non Current Assets Total
Cash And Short Term Investments	- 0.97	Non Current Assets Total
Net Debt	- 0.97	Cash